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Abstract
Background: The choline metabolite, betaine, plays a role in lipid metabolism, and may predict the development
of cardiovascular disease and type 2 diabetes mellitus (T2DM). Phospholipid transfer protein (PLTP) and lecithin:
cholesterol acyltransferase (LCAT) require phosphatidylcholine as substrate, raising the possibility that there is an
intricate relationship of these protein factors with choline metabolism. Here we determined the relationships of
PLTP and LCAT activity with betaine in subjects with and without T2DM.
Methods: Plasma betaine (nuclear magnetic resonance spectroscopy), PLTP activity (liposome-vesicle HDL system),
LCAT activity (exogenous substrate assay) and (apo)lipoproteins were measured in 65 type 2 diabetic (T2DM) and in
55 non-diabetic subjects.
Results: PLTP and LCAT activity were elevated in T2DM (p < 0.05), whereas the difference in betaine was not
significant. In age-, sex- and diabetes status-controlled correlation analysis, betaine was inversely correlated with
triglycerides and positively with HDL cholesterol (p < 0.05 to 0.01). PLTP and LCAT activity were positively correlated
with triglycerides and inversely with HDL cholesterol (p < 0.05 to 0.001). PLTP (r = −0.245, p = 0.006) and LCAT
activity (r = −0.195, p = 0.035) were correlated inversely with betaine. The inverse association of PLTP activity with
betaine remained significant after additional adjustment for body mass index and lipoprotein variables (β = −0.179,
p = 0.034), whereas its association with LCAT activity lost significance (β = −0.056, p = 0.44).
Conclusions: Betaine may influence lipoprotein metabolism via an effect on PLTP activity.
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Background
Choline is regarded as a semi-essential nutrient which origi-
nates from both dietary sources and from de novo produc-
tion in the human body [1]. Choline is to an important
extent oxidized to betaine [1]. Among other effects, betaine
is intricately involved in lipid metabolism as evidenced by its
ability to attenuate hepatic triglyceride accumulation [1]. In
humans, plasma betaine may relate inversely to triglycerides
and non-high density lipoprotein (non-HDL) cholesterol,
and positively to HDL cholesterol [1–3]. In addition, choline
is a component of phosphatidylcholine, a key phospholipid
constituent of lipoproteins and cell membranes [1].
Evidence has accumulated recently that abnormalities
in the choline pathway may be relevant for the develop-
ment of cardiometabolic disorders [4–7]. Thus, low
betaine levels may predict cardiovascular disease (CVD)
in non-diabetic subjects, and modify the extent to which
trimethylamine-N-oxide (TMAO), a metabolite that results
from intestinal choline metabolism, confers an increased
CVD risk [4, 5]. Low betaine levels may also be associated
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with increased incidence of type 2 diabetes mellitus
(T2DM) [6, 7].
Among other factors, human lipoprotein metabolism
is governed by phospholipid transfer protein (PLTP),
which transfers phospholipids, in particular phosphat-
idylcholine, between lipoproteins and is crucial for HDL
remodelling [8, 9], as well as by lecithin:cholesterol acyl-
transferase (LCAT) which generates cholesteryl esters by
using phosphatidylcholine as a substrate [10, 11]. Both
PLTP and LCAT thus play a pivotal role in HDL metab-
olism. Interestingly, in vivo administration of artificial
phosphatidylcholine-apolipoprotein A-I containing parti-
cles enhances the activities of both PLTP and LCAT [12],
suggesting that the activity of these proteins is in part
dependent on phosphatidylcholine. Collectively, these find-
ings [8–10, 12] raise the possibility that choline metabolites
may relate to PLTP and LCAT activity. Furthermore, both
PLTP and LCAT activity have been found to be elevated in
T2DM [9, 11], making the diabetic state a relevant condi-
tion to assess their relationships with betaine.
Here we determined the extent to which plasma PLTP
and LCAT activity are associated with betaine levels in
subjects with and without T2DM.
Methods
Subjects
The study protocol was approved by the medical ethics
committee of the University Medical Center Groningen.
T2DM subjects, aged >18 years, participated after written
informed consent had been obtained. T2DM was diag-
nosed previously by primary care physicians based on a
fasting plasma glucose ≥7.0 mmol/L and/or non-fasting
plasma glucose ≥11.1 mmol/L). The use of metformin,
sulfonylurea and antihypertensive medication was allowed,
but insulin use was an exclusion criterion. Current
smokers and subjects who used lipid lowering drugs were
also excluded, as were subjects with a history of CVD,
chronic kidney disease (estimated glomerular filtration
rate < 60 mL/min/1.73 m2 and/or proteinuria), liver func-
tion abnormalities or thyroid dysfunction. Blood pressure
was measured after 15 min. rest at the left arm in sitting
position using a sphygmomanometer. Body mass index
(BMI in kg/m2) was calculated as weight divided by height
squared. Elevated blood pressure, low HDL cholesterol
and elevated triglycerides were categorized according to
NCEP-ATPIII metabolic syndrome criteria.
Sixty-five diabetic subjects and 55 non-diabetic sub-
jects participated (Table 1). Mean diabetes duration was
5.4 ± 2.1 years. Fourteen T2DM patients used metformin
and 13 used sulfonylurea alone. Both drugs were used by
19 patients. No other glucose lowering drugs were taken.
Anti-hypertensive medication, particularly angiotensin-
converting enzyme inhibitors, angiotensin II receptor
antagonists and diuretics, alone or in combination) were
used by 27 T2DM subjects. None of the non-diabetic sub-
jects used anti-hypertensive drugs (p < 0.001). Three non-
diabetic women (2 post- and 1 premenopausal women)
used estrogens. Other medications were not used.
Laboratory methods
Serum and EDTA-anticoagulated plasma samples were
stored at −80 °C until analysis. Plasma glucose was
measured shortly after blood collection.
Total cholesterol and triglycerides were measured by
routine enzymatic methods (Roche/Hitachi cat. nos
11875540 and 1187602, respectively; Roche Diagnostics
GmBH, Mannheim, Germany). HDL cholesterol was
assayed by a homogeneous enzymatic colorimetric test
(Roche/Hitachi, cat.no 04713214). Non-HDL cholesterol
was calculated as the difference between total cholesterol
and HDL cholesterol. Low density lipoprotein (LDL)
cholesterol was calculated by the Friedewald formula
if triglycerides were < 4.5 mmol/L. Apolipoprotein A-I
(apoA-I) and apolipoprotein B (apoB) were measured by
immunoturbidimetry (Roche/Cobas Integra Tinaquant cat
no. 03032566, Roche Diagnostics). Glucose was analyzed
with an APEC glucose analyzer (APEC Inc., Danvers,
MA). HbA1c was measured by high-performance liquid
chromatography (Bio-Rad, Veenendaal, the Netherlands;
normal range: 27–43 mmol/mol).
PLTP activity (expressed in arbitrary units [AU] rela-
tive to pool plasma) was measured with a liposome vesi-
cles–HDL system [9]. The intra-assay coefficient of
variation of these assays is less than 5 %. Plasma LCAT
activity (expressed in AU relative to pool plasma) was
determined using excess exogenous substrate containing
[3H]-cholesterol [11]. Samples were incubated with la-
belled substrate for 6 h at 37 °C. Corrections were made
for the amount of free cholesterol in the plasma samples.
The reaction was stopped by addition of cold ethanol to
the incubation medium. Free and esterified cholesterol
were separated using disposable silica columns. [3H]-
cholesteryl esters were eluted with hexane. Plasma
LCAT activity is strongly correlated with LCAT concen-
tration. The intra- and interassay coefficients of variation
for PLTP and LCAT activity are < 5 %.
Betaine was measured by 1H-nuclear magnetic reson-
ance (NMR) spectroscopy using a Vantera® NMR Clinical
Analyzer (LabCorp, Raleigh, NC). Plasma specimens
were diluted with citrate/phosphate buffer (3:1 v/v) to
lower the pH to 5.3 in order to separate the betaine and
TMAO signals which overlap at physiological pH. [1H]-
NMR spectra were acquired using the Car-Purcell-Mei-
boom-Gill (CPMG) acquisition technique on a
400 MHz spectrometer (48 scans). The betaine peak
at 3.22 ppm was quantified using a proprietary
bound-constrained non-linear least squares algorithm
that models the lineshape as log-normal and lorentzian
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peak shapes. The derived betaine signal amplitudes were
converted to μmol/L units using a factor that was empiric-
ally determined using dialyzed serum samples spiked with
known amounts of betaine. The betaine quantitation soft-
ware was validated using pooled sera with known amounts
of betaine prepared by serial dilution. The measured beta-
ine values agreed well with expected concentrations
(slope = 0.998, intercept = 0.890, r2 = 0.996). The intra-
and interassay coefficients of variation for betaine are 6.2
and 7.2 %, respectively.
Statistical analysis
SPSS (version 22.0, SPSS Inc. Chicago, IL, USA) was
used for data analysis. Results are expressed as mean ± SD
or as median (interquartile range). Because of skewed dis-
tribution, logarithmically transformed values of triglycer-
ides were used. Between group differences in variables
were determined by unpaired t-tests or by Chi-square
tests. Univariate correlations were determined by Pearson
correlation coefficients. Partial correlation coefficients
were calculated controlling for age, sex and diabetes sta-
tus. Multivariable linear regression analyses were carried
out to disclose the independent relationships of PLTP and
LCAT activity with betaine. Two-sided p-values <0.05
were considered significant.
Results
T2DM subjects were older and more likely to be men
(Table 1). Systolic and diastolic blood pressure, BMI,
glucose and HbA1c were higher in T2DM subjects.
Total cholesterol was lower in T2DM which was in part
attributable to lower HDL cholesterol. Triglycerides
tended to be elevated in T2DM (p = 0.081). High blood
pressure was more prevalent in T2DM vs. non-diabetic
subjects (p < 0.001), but the difference in low HDL
cholesterol (p = 0.074) and elevated triglycerides (p =
0.13) did not reach significance. Non-HDL cholesterol,
LDL cholesterol, apoB and apoA-I levels were not sig-
nificantly different between the groups. Betaine tended
to be lower in T2DM but the difference was not signifi-
cant (p = 0.20). PLTP and LCAT activity were each in-
creased in T2DM subjects (Table 1). Betaine, PLTP and
LCAT activity were not different between men and
women (p > 0.10 for each; data not shown). In the
whole group, betaine (r = −0.144, p = 0.12) and LCAT
activity (r = 0.072, p = 0.43) were unrelated to age, but
Table 1 Clinical characteristics, plasma (apo)lipoproteins, betaine, phospholipid transfer protein (PLTP) activity and lecithin:cholesterol
acyltransferase (LCAT) activity in 65 Type 2 diabetic (T2DM) patients and in 55 non-diabetic subjects, and partial correlation coefficients
with betaine, PLTP activity and LCAT activity in whole study group
Partial correlation coefficient of variable with
T2DM subjects (n = 65) Non-diabetic subjects (n= 55) Betaine PLTP activity LCAT activity
Age (years) 59 ± 9** 54 ± 10
Sex (men/women) 40/25* 23/32
Systolic blood pressure (mm Hg) 146 ± 20*** 130 ± 20 −0.04 0.033 0.033
Diastolic blood pressure (mm Hg) 87 ± 9* 82 ± 11 −0.172 0.061 0.237*
BMI (kg/m2) 28.9 ± 4.9*** 25.8 ± 4.1 −0.036 0.229* 0.242*
Glucose (mmol/L) 8.95 ± 2.33*** 5.65 ± 0.62 −0.225* 0.171 0.390***
HbA1c (mmol/mol) 50 ± 5*** 34 ± 2 −0.245** 0.199* 0.306***
Total cholesterol (mmol/L) 5.34 ± 0.92* 5.76 ± 0.97 −0.144 0.225* 0.544***
Non-HDL cholesterol (mmol/L) 4.04 ± 1.09 4.23 ± 1.05 −0.209* 0.281** 0.590***
LDL cholesterol (mmol/L) 3.21 ± 0.84 3.50 ± 0.86 −0.139 0.167 0.457***
HDL cholesterol (mmol/L) 1.30 ± 0.39** 1.53 ± 0.40 0.218* −0.213* −0.265**
Triglycerides (mmol/L) 1.73 (1.20–2.17) 1.37 (0.88–1.92) −0.239** 0.312*** 0.614***
ApoB (g/L) 0.92 ± 0.23 0.95 ± 0.24 −0.138 0.252** 0.493***
ApoA-I (g/L) 1.36 ± 0.24 1.43 ± 0.21 0.057 −0.139 0.040
Betaine (μmol/L) 24.5 ± 10.3 26.7 ± 9.0
PLTP activity (AU) 104.3 ± 11.6*** 94.5 ± 10.5 −0.254**
LCAT activity (AU) 114.5 ± 17.7* 107.6 ± 13.3 −0.195* 0.135
Data are means ± SD or medians (interquartile range)
BMI body mass index, HbA1c glycated hemoglobin, apo apolipoprotein, HDL high density lipoproteins, LDL low density lipoproteins. LDL cholesterol was calculated
in 62 T2DM subjects and in 53 non-diabetic subjects. Partial correlation coefficients controlling for age, sex and diabetes status are shown
*p < 0.05; **p ≤ 0.01; ***p ≤ 0.001
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PLTP activity tended to be higher with advancing age
(r = 0.164, p = 0.073).
In the whole group, betaine was correlated inversely
with PLTP activity (r = −0.307, p = 0.001) and with LCAT
activity (r = −0.223, p = 0.014) in univariate analysis. In
T2DM subjects separately, betaine also (tended to be)
inversely related to PLTP activity (r = −0.447, p < 0.001)
and LCAT activity (r = −0.238, p = 0.056). These rela-
tionships were non-significant in non-diabetic subjects
(r = −0.046, p = 0.75 and r = −0.145, p = 0.29, respectively).
After controlling for age, sex and diabetes status, betaine
was correlated inversely with glycemia, non-HDL choles-
terol and triglycerides, and positively with HDL choles-
terol (Table 1). PLTP and LCAT activity were correlated
positively with BMI, glycemia, total cholesterol and non-
HDL cholesterol, triglycerides and apoB, and inversely
with HDL cholesterol. Betaine was correlated inversely
with both PLTP and LCAT activity (Table 1).
Multivariable linear regression analyses were carried
out to discern the independent associations PLTP activity
and LCAT activity with betaine (Table 2). In analyses in
which we adjusted for age, sex, diabetes status, BMI and
lipoprotein variables (representing variables to which beta-
ine, PLTP and/or LCAT activity were correlated in age-,
sex- and diabetes status-adjusted analysis as shown in
Table 1), PLTP activity was independently and inversely
associated with betaine (Table 2A, model 1). A similar in-
verse association was found when lipoprotein variables
were replaced by apoB and apoA-I (Table 2A, model 2).
These relationships remained essentially unaltered after
additional adjustment for the use of glucose lowering
drugs or antihypertensive medication (β = −0.204 to −0.16,
p = 0.015 to p = 0.052; data not shown). Of note, the asso-
ciation of LCAT activity with betaine was no longer sig-
nificant after adjustment for age, sex, diabetes status, BMI
and lipoprotein variables or apolipoproteins (Table 2B,
models 1 and 2). This association was also not significant
after additional adjustment for glucose lowering drugs
or antihypertensive medication use (β = −0.138 to −0.044,
p = 0.093 to p = 0.54; data not shown).
Discussion
In this study, we used a newly developed NMR
spectrocopy-based assay to determine plasma betaine.
Plasma betaine was correlated inversely with triglycer-
ides and positively with HDL cholesterol. In contrast,
PLTP and LCAT activity were correlated positively with
triglycerides and inversely with HDL cholesterol. Both
PLTP and LCAT activity were correlated inversely with
betaine in univariate and in age-, sex- and diabetes
status-adjusted analysis, but only the relationship with
PLTP activity remained statistically significant in analysis
in which we additionally controlled for BMI and (apo)li-
poprotein variables. Our findings raise the possibility
that betaine, an oxidation product of choline metabol-
ism, could influence lipoprotein metabolism via an effect
on PLTP activity.
Given the relevance of PLTP and LCAT for altered
HDL remodelling and triglyceride metabolism in dia-
betes [9–11, 13], we decided to include both diabetic
and non-diabetic subjects in the present study. Plasma
PLTP and LCAT activity were expectedly elevated in
T2DM, and both protein factors were correlated posi-
tively with triglycerides [9, 11, 13, 14]. Betaine was not
significantly different between diabetic and non-diabetic
subjects, despite being inversely correlated with glucose
and HbA1c. In comparison, betaine has been variably re-
ported to be lower [6] or unchanged in T2DM [15].
In keeping with earlier reports, betaine was related in-
versely to triglycerides and non-HDL cholesterol, and
Table 2 Multivariable linear regression analysis showing
associations of plasma phospholipid transfer protein (PLTP) activity
(A) and lecithin:cholesterol acyltransferase (LCAT) activity (B) as
dependent variables with clinical variables, (apo)lipoproteins and
betaine as statistical determinants
Model 1 Model 2
β p-value β p-value
A. PLTP activity
Age 0.076 0.37 0.078 0.36
Sex (men/women) −0.139 0.14 −0.163 0.07
Diabetes (yes/no) 0.340 <0.001 0.339 <0.001
BMI 0.176 0.06 0.181 0.043
Non-HDL cholesterol 0.126 0.22
HDL cholesterol 0.064 0.59
Triglycerides 0.146 0.232
Apolipoprotein B 0.166 0.05
Apolipoprotein A-I −0.014 0.88
Betaine −0.179 0.034 −0.204 0.014
B. LCAT activity
Age 0.007 0.92 −0.003 0.97
Sex (men/women) 0.004 0.96 −0.006 0.95
Diabetes (yes/no) 0.186 0.018 0.188 0.034
BMI 0.154 0.053 0.217 0.013
Non-HDL cholesterol 0.344 <0.001
HDL cholesterol 0.304 0.003
Triglycerides 0.505 <0.001
Apolipoprotein B 0.490 <0.001
Apolipoprotein A-I 0.198 0.033
Betaine −0.056 0.44 −0.130 0.10
β standardized regression coefficients, BMI body mass index, HDL high density
lipoproteins. Triglycerides levels are logarithmically transformed
Model 1: includes age, sex, diabetes status, BMI, plasma non-HDL cholesterol,
HDL cholesterol, triglycerides and betaine as independent variables
Model 2: includes age, sex, diabetes status, BMI, apolipoprotein B,
apolipoprotein A-I and betaine as independent variables
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positively with HDL cholesterol [1–3]. Of note, both
betaine and PLTP affect hepatic triglyceride metabolism
although by different mechanisms [16, 17]. Moreover,
not only plasma betaine but also PLTP activity has been
suggested to predict incident T2DM [6, 7, 14]. Thus, in
view of the presently documented inverse relationship
between PLTP and betaine, it seems warranted to take
both factors into consideration when evaluating the extent
to which they may confer cardiometabolic risk [4, 5, 18].
Several methodological considerations and limitations
of our study need to be appreciated. First, we conducted
a cross-sectional study in a rather restricted number of
participants. Thus, cause-effect relationships cannot be
established with certainty. Second, we excluded subjects
who used lipid lowering treatment. As a result, it is likely
that diabetic subjects with mild lipoprotein abnormal-
ities were preferentially included, limiting extrapolation
of the current findings to subjects with more severe dys-
lipidemia. Third, it is obvious that the explorative design
of our study necessitates to delineate more precisely the
metabolic interplay between the generation of betaine
from choline on the one hand and the conversion of
choline to phosphatidylcholine on the other.
Conclusions
Our present results are consistent with the concept that
the choline metabolite, betaine, may influence lipopro-
tein metabolism via an effect on PLTP activity.
Acknowledgments
Plasma lipid and apolipoprotein measurement was carried out in the laboratory
of Dr. L.D. Dikkeschei, PhD, Department of Clinical Chemistry, Isala Clinics
Zwolle, The Netherlands. Plasma PLTP activity was measured in the laboratory
of Dr. GM. Dallinga-Thie, Department of Experimental Vascular Medicine,
Academic Medical Center, Amsterdam, The Netherlands. Dr. F. Perton,
Laboratory Center, University of Groningen, The Netherlands, carried out
the LCAT assays.
Funding
No financial support from an external agency was used for this study.
Availability of data and material
Proprietary algorithms used to generate the data in this manuscript will not
be made available for general use as they are proprietary to LabCorp. Data
may be made available by request to the corresponding author.
Author’s contributions
RPFD performed the statistical analyses, interpreted the data and wrote the
manuscript. EGG interpreted the data. EG and EJ developed the betaine
assay, generated the betaine data and edited the manuscript. EG and MAC
contributed to data interpretation and edited the manuscript. All authors
read and approved the final manuscript.
Competing interests
This study is investigator initiated. EG, EJ and MAC are employees of Laboratory
Corporation of America® Holdings (LabCorp). Betaine measurements were
performed by LabCorp (Raleigh, North Carolina, USA) at no cost.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study protocol was approved by the medical ethics committee of the
University Medical Center Groningen.
Author details
1Department of Endocrinology, University Medical Center Groningen, University
of Groningen, P.O. Box 30.001, Groningen 9700 RB, The Netherlands.
2LipoScience, Laboratory Corporation of America® Holdings, Raleigh, NC, USA.
3Departments of Endocrinology and Nephrology, University of Groningen and
University Medical Center Groningen, Groningen, The Netherlands.
Received: 15 July 2016 Accepted: 23 August 2016
References
1. Ueland PM. Choline and betaine in health and disease. Inherit Metab Dis.
2011;34:3–15.
2. Konstantinova SV, Tell GS, Vollset SE, Nygård O, Bleie Ø, Ueland PM.
Divergent associations of plasma choline and betaine with components of
metabolic syndrome in middle age and elderly men and women. J Nutr.
2008;138:914–20.
3. Lever M, George PM, Atkinson W, Molyneux SL, Elmslie JL, Slow S, et al.
Plasma lipids and betaine are related in an acute coronary syndrome
cohort. PLoS One. 2011;6:e21666.
4. Lever M, George PM, Slow S, Bellamy D, Young JM, Ho M, et al. Betaine and
trimethylamine-N-oxide as predictors of cardiovascular outcomes show
different patterns in diabetes mellitus: an observational study. PLoS One.
2014;9:e114969.
5. Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, et al. Prognostic value
of choline and betaine depends on intestinal microbiota-generated
metabolite trimethylamine-N-oxide. Eur Heart J. 2014;35:904–10.
6. Svingen GF, Schartum-Hansen H, Pedersen ER, Ueland PM, Tell GS, Mellgren
G, et al. Prospective associations of systemic and urinary choline
metabolites with incident type 2 diabetes. Clin Chem. 2016;62:755–65.
7. Walford GA, Ma Y, Clish C, Florez JC, Wang TJ, Gerszten RE, Group DPPR.
Metabolite profiles of diabetes incidence and intervention response in the
diabetes prevention program. Diabetes. 2016;65:1424–33.
8. Nishida H, Nishida T. Phospholipid transfer protein mediates transfer of
not only phosphatidylcholine but also cholesterol from phosphatidylcholine-
cholesterol vesicles to high density lipoproteins. J Biol Chem.
1997;272:6959–64.
9. Dullaart RPF, Vergeer M, de Vries R, Kappelle PJ, Dallinga-Thie GM. Type 2
diabetes mellitus interacts with obesity and common variations in PLTP
to affect plasma phospholipid transfer protein activity. J Intern Med.
2012;271:490–8.
10. Santamarina-Fojo S, Lambert G, Hoeg JM, Brewer Jr HB. Lecithin-cholesterol
acyltransferase: role in lipoprotein metabolism, reverse cholesterol transport
and atherosclerosis. Curr Opin Lipidol. 2000;11:267–75.
11. Dullaart RPF, Perton F, Sluiter WJ, de Vries R, van Tol A. Plasma lecithin:
cholesterol acyltransferase activity is elevated in metabolic syndrome and is
an independent marker of increased carotid artery intima media thickness.
J Clin Endocrinol Metab. 2008;93:4860–6.
12. Kujiraoka T, Nanjee MN, Oka T, Ito M, Nagano M, Cooke CJ, et al. Effects of
intravenous apolipoprotein A-I/phosphatidylcholine discs on LCAT, PLTP,
and CETP in plasma and peripheral lymph in humans. Arterioscler Thromb
Vasc Biol. 2003;23:1653–9.
13. Dallinga-Thie GM, Dullaart RP, van Tol A. Concerted actions of cholesteryl
ester transfer protein and phospholipid transfer protein in type 2 diabetes:
effects of apolipoproteins. Curr Opin Lipidol. 2007;18:251–7.
14. Abbasi A, Dallinga-Thie GM, Dullaart RPF. Phospholipid transfer
protein activity and incident type 2 diabetes mellitus. Clin Chim Acta.
2015;439:38–41.
15. Obeid R, Awwad HM, Rabagny Y, Graeber S, Herrmann W, Geisel J. Plasma
trimethylamine N-oxide concentration is associated with choline,
phospholipids, and methyl metabolism. Am J Clin Nutr. 2016;103:703–11.
16. Wang L, Chen L, Tan Y, Wei J, Chang Y, Jin T, Zhu H. Betaine supplement
alleviates hepatic triglyceride accumulation of apolipoprotein E deficient
mice via reducing methylation of peroxisomal proliferator-activated
receptor alpha promoter. Lipids Health Dis. 2013;12:34.
Dullaart et al. Lipids in Health and Disease  (2016) 15:143 Page 5 of 6
17. Lie J, de Crom R, van Gent T, van Haperen R, Scheek L, Lankhuizen I, et al.
Elevation of plasma phospholipid transfer protein in transgenic mice
increases VLDL secretion. J Lipid Res. 2002;43:1875–80.
18. Vergeer M, Boekholdt SM, Sandhu MS, Ricketts SL, Wareham NJ, Brown MJ,
et al. Genetic variation at the phospholipid transfer protein locus affects its
activity and high-density lipoprotein size and is a novel marker of
cardiovascular disease susceptibility. Circulation. 2010;122:470–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Dullaart et al. Lipids in Health and Disease  (2016) 15:143 Page 6 of 6
